Alice Mims, MD, MSCR
College of Medicine
Dr. Mims' clinical/translational research focus is on novel therapeutics in Acute Myeloid Leukemia (AML), in particular, for patients with high-risk disease such as the elderly (= 60 years), TP53 mutated, and relapsed/refractory disease. Her laboratory background began in medical school and continued through fellowship with a NIH T32 supported research in mechanisms and microRNA targets in AML treatment. Dr. Mims is currently the acute leukemia disease group leader in clinical investigation. She has authored multiple clinical trial proposals in AML and have been the site principal investigator for both investigator-initiated and industry supported AML studies in both upfront and relapsed/refractory disease. She is currently the lead PI on a multi-center study investigating novel treatment in elderly AML patients though the Leukemia Lymphoma Society Beat AML study.
Post-doctoral, Medical University of South Carolina
Charleston, SC (USA)